Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation

Journal of Heart and Lung Transplantation

Volumn 29, Issue 6, 2010, Pages 641-647

  Gude, Einar ^a   Gullestad, Lars ^a,b   Arora, Satish ^b   Simonsen, Svein ^a   Hoel, Ina ^a   Hartmann, Anders ^a,b   Holdaas, Hallvard ^a   Fiane, Arnt E ^a,b   Geiran, Odd R ^a,b   Andreassen, Arne K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

everolimus; heart transplantation; immunosuppression; rejections; renal failure

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LONGITUDINAL STUDY; MALE; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; SURVIVOR; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; CONVALESCENCE; DRUG EFFECTS; GRAFT REJECTION; INCIDENCE; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RETREATMENT; TIME;

CALCINEURIN; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RECOVERY OF FUNCTION; RETREATMENT; SIROLIMUS; SURVIVORS; TIME FACTORS; CALCINEURIN INHIBITORS;

EID: 77952545939     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.01.005     Document Type: Article

References (30)

1. Taylor D.O., Edwards L.B., Aurora P., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 27 (2008) 943-956
2. Schmauss D., and Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 117 (2008) 2131-2141
3. Caforio A.L., Tona F., Piaserico S., et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transplant Int 1 (2005) 116-124
4. Arora S., Andreassen A., Simonsen S., et al. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy. Transplantation 84 (2007) 149-154
5. Cantarovich M., Hirsh A., Alam A., et al. The clinical impact of an early decline in kidney function in patients following heart transplantation. Am J Transplant 9 (2009) 348-354
6. Chapman J.R., Valantine H., Albanell J., et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 10 (2007) 2937-2950
7. Gustafsson F., and Ross H.J. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol 2 (2007) 111-116
8. Rothenburger M., Zuckermann A., Bara C., et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 4 (2007) 305-311
9. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
10. Lehmkuhl H.B., Mai D., Dandel M., et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 7 (2007) 700-704
11. Meier-Kriesche H.U., Schold J., Srinivas T., et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5 (2005) 2273-2280
12. Meier-Kriesche, Steffen B., Chu A., et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 4 (2004) 2058-2066
13. Moro López J.A., Almenar L., Martínez-Dolz L., et al. Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime. Transplantation 87 (2009) 538-541
14. Lehmkuhl H., and Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 24 suppl (2005) S201-S205
15. Rothenburger M., Teerling E., Bruch C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 3 (2007) 250-257
16. Gonzalez-Vilchez F., de Prada J.A., Exposito V., et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 10 (2008) 1135-1141
17. Holdaas H., Bentdal O., Pfeffer P., et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 3 (2008) 366-371
18. Watson C.J., Firth J., Williams P., et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5 (2005) 2496-2503
19. Kovarik J.M., Kalbag J., Figueiredo J., et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 42 (2002) 95-99
20. Gullestad L, Iversen M, Mortensen A. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with reduced renal function: a multicenter, randomized trial. Transplantation (Epub ahead of print).
21. Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection. Study NCT00300274. A 2310-study. www.clinicaltrials.gov
22. van Gelder T., Klupp J., Sawamoto T., et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. Transplant Proc 3 (2001) 2420-2421
23. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
24. Bocchi E.A., Ahualli L., Amuchastegui M., et al. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Transplant Proc 38 (2006) 937-942
25. Nankivell B.J., Borrows R.J., Fung C.L., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004) 557-565
26. Meiser B., Reichart B., Adamidis I., et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 4 (2005) 827-831
27. Zuckermann A., Manito N., Epailly E., et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2 (2008) 141-149
28. Zakliczynski M., Nozynski J., Zakliczynska H., et al. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 6 (2003) 2331-2332
29. Vitko S., Margreiter R., Weimar W., et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532-1540
30. Stephany B.R., Boumitri M., Budev M., et al. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 6 (2009) 564-571